Baricitinib in Idiopathic Granulomatous Mastitis
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Study ID
- NCT05852171
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Idiopathic Granulomatous Mastitis
- Mastitis Chronic
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib — DRUGBaricitinib administered orally
Study Details
This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.
Key Dates
- Start date
- May 4, 2023
- Status verified
- May 2024
- Primary completion
- Apr 30, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BaricitinibBaricitinib，2mg QD，oral use.
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Until progression or recurrence, assessed up to approximately 24 months post-intervention ]